SCHEMBL23579371

SCHEMBL23579371

O=C1NC(=O)/C(=C/c2csc3ccccc23)S1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 3/20 0.75
▸ TDP1 Q9NUW8 2/20 0.75
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ TTR P02766 2/20 0.61
▸ AKR1B1 P15121 2/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ MAPT P10636 1/20 0.61
▸ PKM P14618 1/20 0.61
▸ KDM4C Q9H3R0 1/20 0.61
▸ IGF1R P08069 2/20 0.56
▸ NAT1 P18440 1/20 0.56
▸ PIM3 Q86V86 2/20 0.55
▸ PIM2 Q9P1W9 2/20 0.55
▸ GSK3B P49841 4/20 0.52
▸ TDP2 O95551 1/20 0.51
▸ CASP7 P55210 1/20 0.51
▸ CASP9 P55211 1/20 0.51
▸ CASP6 P55212 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23579374 1.00 PIM1 (0.75) PIM1TDP1MEN1KMT2ATTR
SCHEMBL14860982 0.86 TDP1 (1.00) PIM1TDP1MEN1KMT2AKDM4E
SCHEMBL23578866 0.86 PIM1 (1.00) PIM1TDP1MEN1KMT2AKDM4E
SCHEMBL23578868 0.86 PIM1 (1.00) PIM1TDP1MEN1KMT2AKDM4E
SCHEMBL14860983 0.86 TDP1 (1.00) PIM1TDP1MEN1KMT2AKDM4E
SCHEMBL14860985 0.86 TDP1 (1.00) PIM1TDP1MEN1KMT2AKDM4E
SCHEMBL26425877 0.78 TTR (0.52) PIM1TDP1MEN1KMT2ATTR
SCHEMBL1248821 0.76 KMT2A (1.00) PIM1MEN1KMT2ATTRAKR1B1
SCHEMBL1248823 0.76 KMT2A (1.00) PIM1MEN1KMT2ATTRAKR1B1
SCHEMBL1247523 0.75 PIM1 (0.72) PIM1MEN1KMT2ATTRAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 — — US claimed
EP-4083037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME Yonsei University, University-Industry Foundation(UIF). (KR) 2022-11-02 — — EP claimed
CN-114945569-A Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same 延世大学校产学协力团 2022-08-26 — — CN claimed
WO-2021133037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME 연세대학교 산학협력단 2021-07-01 — — WO claimed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 — — US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 — — US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 — — US disclosed
EP-4083037-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME Yonsei University, University-Industry Foundation(UIF). (KR) 2022-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP PIM1 3071/4885TDP1 110/4885MEN1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback